GlassScriptPhysician profile
Foster Donald Lasley
NPI 1407083058
$8,144.87
in general payments reported to CMS, 2019-2025
59 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 85% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $1,248 · 2021: $979 · 2022: $1,699 · 2023: $1,246 · 2024: $876 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,259.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $770.35 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $739.35 | 2019-2025 | |
| Eisai INC. | $575.39 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $463.74 | 2019-2025 | Libtayo |
| Amgen INC. | $388.66 | 2019-2022 | |
| Beigene USA, INC. | $347.62 | 2020-2023 | Brukinsa |
| Celgene Corporation | $345.33 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $286.86 | 2020-2025 | Enhertu, Imfinzi, Tagrisso |
| Puma Biotechnology, INC. | $282.24 | 2019-2025 | |
| Janssen Biotech, INC. | $276.92 | 2020-2025 | Rybrevant, Darzalex, Carvykti |
| Bayer Healthcare Pharmaceuticals INC. | $246.25 | 2019-2023 | |
| Exelixis INC. | $234.95 | 2019-2025 | Cabometyx |
| Rigel Pharmaceuticals, INC. | $213.41 | 2020-2023 | Rezlidhia, Tavalisse |
| Daiichi Sankyo INC. | $209.55 | 2022-2025 | Enhertu, Datroway |
| Genzyme Corporation | $176.07 | 2019-2025 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $149.50 | 2020-2023 | Tukysa, Adcetris, Padcev |
| Coherus Oncology, INC. | $145.76 | 2020-2021 | |
| Lilly USA, LLC | $141.04 | 2020-2025 | Verzenio, Jaypirca |
| Incyte Corporation | $139.05 | 2021-2024 | Jakafi, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $118.10 | 2019-2025 | Ninlaro, Fruzaqla |
| Pharmacyclics LLC, An Abbvie Company | $117.65 | 2022-2023 | Imbruvica |
| Sirtex Medical INC | $104.07 | 2024 | Sir-Spheres Microspheres |
| Karyopharm Therapeutics INC. | $103.44 | 2020-2022 | |
| Sobi, INC | $99.40 | 2022-2025 | |
| Dendreon Pharmaceuticals LLC | $96.51 | 2019-2025 | Provenge |
| Clovis Oncology, INC. | $89.73 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $87.05 | 2021-2025 | Onivyde |
| Myriad Genetic Laboratories, INC. | $80.15 | 2023 | Prolaris, Myrisk |
| Elekta, INC. | $73.02 | 2023 | Elekta Medical Linear Accelerator |
| Abbvie INC. | $70.32 | 2024-2025 | |
| Myovant Sciences INC. | $64.95 | 2022 | |
| Aveo Pharmaceuticals, INC. | $63.56 | 2022-2025 | Fotivda |
| Sun Pharmaceutical Industries INC. | $60.21 | 2020-2024 | |
| Stemline Therapeutics INC. | $56.79 | 2025 | Orserdu |
| Spectrum Pharmaceuticals INC. | $51.04 | 2023-2025 | Rolvedon |
| Pfizer INC. | $48.45 | 2021-2025 | |
| Astellas Pharma US INC | $42.01 | 2020-2021 | |
| Blue Earth Diagnostics | $40.23 | 2023 | |
| G1 Therapeutics, INC. | $38.57 | 2022-2023 | Cosela |
| Menarini Silicon Biosystems, INC. | $36.06 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.55 | 2021-2023 | Gilotrif |
| Kyowa Kirin, INC. | $35.34 | 2020-2023 | Poteligeo |
| Morphosys, US INC. | $34.47 | 2021-2024 | Monjuvi |
| Genentech USA, INC. | $34.06 | 2022-2025 | Tecentriq |
| Cti Biopharma Corp. | $32.70 | 2023 | Vonjo |
| Taiho Oncology, INC. | $31.26 | 2022-2024 | |
| Iovance Biotherapeutics, INC. | $30.58 | 2025 | Amtagvi |
| Fortovia Therapeutics, INC. | $29.65 | 2019 | |
| Emd Serono, INC. | $28.03 | 2023-2024 | Tepmetko |
| Progenics Pharmaceuticals, INC. | $26.74 | 2022 | |
| Novocure INC. | $25.31 | 2023 | Optune |
| Boston Scientific Corporation | $19.42 | 2021 | |
| Mirati Therapeutics, INC. | $19.20 | 2024 | Krazati |
| Syndax Pharmaceuticals, INC. | $17.13 | 2025 | |
| Jazz Pharmaceuticals INC. | $16.11 | 2025 | |
| Caris Mpi, INC. | $15.45 | 2025 | Mi Cancer Seek |
| Adc Therapeutics America, INC. | $13.94 | 2024 | |
| Pharmaessentia USA Corporation | $13.46 | 2025 | Besremi |
| Pharmacosmos Therapeutics INC. | $13.12 | 2024 | Cosela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Foster Lasley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.